PharmacoEconomics & Outcomes News 687, p10 - 21 Sep 2013 Pazopanib better QOL than sunitinib in mRCC Pazopanib and sunitinib are tyrosine kinase inhibitors and first-line treatment options for patients with metastatic renal-cell carcinoma (mRCC). Results from the first large (n = 1110) phase III trial to compare these agents have shown that, although both treatments have similar clinical efficacy, safety and QOL profiles favour pazopanib. Pazopanib was non-inferior to sunitinib in median progression-free survival (8.4 vs 9.5 months; hazard ratio [HR] 1.05; 95% CI 0.90, 1.22). Non-inferiority was also shown for median overall survival (28.4 vs 29.3 months; HR 0.91; 0.76, 1.08). However, grade 3 or 4 fatigue, hand-foot syndrome and mucosal inflammation were more common in sunitinib than pazopanib recipients. Although no grade 3 or 4 adverse event occurred significantly more often in pazopanib than sunitinib recipients, discontinuation because of adverse events was more common with pazopanib (24% vs 20%), primarily due to abnormalities in liver function tests (6% vs 1%). In 11 of 14 health-related QOL domains for the first 6 months of treatment, pazopanib was associated with significantly more favourable changes from baseline, especially in relation to fatigue or soreness in the mouth, throat, hands or feet (p < 0.05). Pazopanib recipients also had fewer monthly telephone consultations (p = 0.04) and emergency department visits (p = 0.003) than sunitinib recipients. Motzer RJ, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine 369: 722-731, No. 8, 22 Aug 2013. Available from: URL: http://dx.doi.org/10.1056/NEJMoa1303989 803092967 1 PharmacoEconomics & Outcomes News 21 Sep 2013 No. 687 1173-5503/13/0687-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved

Pazopanib better QOL than sunitinib in mRCC

Download PDF Report

Upload
nguyenthien
View
212
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 687, p10 - 21 Sep 2013

Pazopanib better QOL thansunitinib in mRCC

Pazopanib and sunitinib are tyrosine kinase inhibitorsand first-line treatment options for patients withmetastatic renal-cell carcinoma (mRCC). Results fromthe first large (n = 1110) phase III trial to compare theseagents have shown that, although both treatments havesimilar clinical efficacy, safety and QOL profiles favourpazopanib.

Pazopanib was non-inferior to sunitinib in medianprogression-free survival (8.4 vs 9.5 months; hazardratio [HR] 1.05; 95% CI 0.90, 1.22). Non-inferiority wasalso shown for median overall survival (28.4 vs 29.3months; HR 0.91; 0.76, 1.08). However, grade 3 or 4fatigue, hand-foot syndrome and mucosal inflammationwere more common in sunitinib than pazopanibrecipients. Although no grade 3 or 4 adverse eventoccurred significantly more often in pazopanib thansunitinib recipients, discontinuation because of adverseevents was more common with pazopanib (24% vs20%), primarily due to abnormalities in liver functiontests (6% vs 1%).

In 11 of 14 health-related QOL domains for the first6 months of treatment, pazopanib was associated withsignificantly more favourable changes from baseline,especially in relation to fatigue or soreness in the mouth,throat, hands or feet (p < 0.05). Pazopanib recipientsalso had fewer monthly telephone consultations(p = 0.04) and emergency department visits (p = 0.003)than sunitinib recipients.Motzer RJ, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma.New England Journal of Medicine 369: 722-731, No. 8, 22 Aug 2013. Availablefrom: URL: http://dx.doi.org/10.1056/NEJMoa1303989 803092967